Geron Corp. (GERN)
0.8707
-0.04
(-4.63%)
USD |
NASDAQ |
Nov 20, 16:00
0.8696
0.00 (0.00%)
After-Hours: 20:00
Geron Enterprise Value : 522.84M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 522.84M |
| November 19, 2026 | 550.09M |
| November 18, 2026 | 600.27M |
| November 17, 2026 | 606.14M |
| November 16, 2026 | 568.71M |
| November 13, 2026 | 584.88M |
| November 12, 2026 | 602.27M |
| November 11, 2026 | 619.02M |
| November 10, 2026 | 589.52M |
| November 09, 2026 | 603.88M |
| November 06, 2026 | 599.57M |
| November 05, 2026 | 573.99M |
| November 04, 2026 | 657.68M |
| November 03, 2026 | 561.04M |
| November 02, 2026 | 560.46M |
| October 30, 2026 | 538.11M |
| October 29, 2026 | 571.48M |
| October 28, 2026 | 585.84M |
| October 27, 2026 | 702.77M |
| October 26, 2026 | 702.77M |
| October 23, 2026 | 683.45M |
| October 22, 2026 | 689.89M |
| October 21, 2026 | 709.22M |
| October 20, 2026 | 760.75M |
| October 19, 2026 | 734.98M |
| Date | Value |
|---|---|
| October 16, 2026 | 715.66M |
| October 15, 2026 | 754.31M |
| October 14, 2026 | 728.54M |
| October 13, 2026 | 734.98M |
| October 12, 2026 | 747.87M |
| October 09, 2026 | 751.09M |
| October 08, 2026 | 747.87M |
| October 07, 2026 | 734.98M |
| October 06, 2026 | 741.43M |
| October 05, 2026 | 741.43M |
| October 02, 2026 | 734.98M |
| October 01, 2026 | 741.43M |
| September 30, 2026 | 754.31M |
| September 29, 2026 | 745.69M |
| September 28, 2026 | 752.12M |
| September 25, 2026 | 758.54M |
| September 24, 2026 | 758.54M |
| September 23, 2026 | 745.69M |
| September 22, 2026 | 790.67M |
| September 21, 2026 | 784.24M |
| September 18, 2026 | 784.24M |
| September 17, 2026 | 797.09M |
| September 16, 2026 | 777.82M |
| September 15, 2026 | 790.67M |
| September 14, 2026 | 829.22M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 453.57M |
| Amgen, Inc. | 276.45B |
| Anika Therapeutics, Inc. | 158.39M |
| BioCryst Pharmaceuticals, Inc. | 2.302B |
| Imunon, Inc. | 6.224M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.35M |
| Revenue (Quarterly) | 60.19M |
| Total Expenses (Quarterly) | 58.84M |
| EPS Diluted (Quarterly) | 0.002 |
| Gross Profit Margin (Quarterly) | 89.95% |
| Profit Margin (Quarterly) | 2.24% |
| Earnings Yield | -8.61% |
| Normalized Earnings Yield | -6.638 |